What is required to advance data ethics, data sharing, and Open Science across LMICs

Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic leukaemia and small lymphocytic lymphoma

A genomic assay may predict long-term prognosis in premenopausal patients with HR+ early-stage breast cancer

Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response in previously untreated CLL enriched for high-risk disease

Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and OS in patients with high-risk HR+, HER2-negative BC

Opinion: Premature regulatory approval by the FDA

Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma

Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows promising results in patients with multiple myeloma

The future of precision oncology

The concept of pan-tumour therapeutics

Access to Oncology Medicines Coalition - The Medicines Patent Pool

Systemic anti-cancer performance matrix